207 related articles for article (PubMed ID: 23062244)
1. In silico assessment of adverse effects of a large set of 6-fluoroquinolones obtained from a study of tuberculosis chemotherapy.
Tusar M; Minovski N; Fjodorova N; Novic M
Curr Drug Saf; 2012 Sep; 7(4):313-20. PubMed ID: 23062244
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling.
Nandi S; Ahmed S; Saxena AK
SAR QSAR Environ Res; 2018 Feb; 29(2):151-170. PubMed ID: 29347843
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone derivatives and their anti-tubercular activities.
Fan YL; Wu JB; Cheng XW; Zhang FZ; Feng LS
Eur J Med Chem; 2018 Feb; 146():554-563. PubMed ID: 29407980
[TBL] [Abstract][Full Text] [Related]
5. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis.
Minovski N; Perdih A; Novic M; Solmajer T
J Comput Chem; 2013 Apr; 34(9):790-801. PubMed ID: 23280926
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
Pranger AD; Alffenaar JW; Aarnoutse RE
Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.
Ho J; Jelfs P; Sintchenko V
Int J Infect Dis; 2014 Sep; 26():149-53. PubMed ID: 25086437
[TBL] [Abstract][Full Text] [Related]
9. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
Mayer C; Takiff H
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
[TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
[TBL] [Abstract][Full Text] [Related]
12. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
Chaoui I; Oudghiri A; El Mzibri M
J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
Zhou FW; Lei HS; Fan L; Jiang L; Liu J; Peng XM; Xu XR; Chen L; Zhou CH; Zou YY; Liu CP; He ZQ; Yang DC
Bioorg Med Chem Lett; 2014 Apr; 24(8):1912-7. PubMed ID: 24684842
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
15. QSAR based therapeutic management of M. tuberculosis.
Ahamad S; Rahman S; Khan FI; Dwivedi N; Ali S; Kim J; Imtaiyaz Hassan M
Arch Pharm Res; 2017 Jun; 40(6):676-694. PubMed ID: 28456911
[TBL] [Abstract][Full Text] [Related]
16. QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis.
Kovalishyn V; Brovarets V; Blagodatnyi V; Kopernyk I; Hodyna D; Chumachenko S; Shablykin O; Kozachenko O; Vovk M; Barus M; Bratenko M; Metelytsia L
Curr Drug Discov Technol; 2017; 14(1):25-38. PubMed ID: 27829331
[TBL] [Abstract][Full Text] [Related]
17. Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment.
Minovski N; Perdih A; Solmajer T
J Mol Model; 2012 May; 18(5):1735-53. PubMed ID: 21833830
[TBL] [Abstract][Full Text] [Related]
18. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
Jabeen K; Shakoor S; Malik F; Hasan R
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships on purine and 2,3-dihydropurine derivatives as antitubercular agents: a data mining approach.
Pietra D; Imbriani M; Borghini A; Giorgi I; Settimo FD; Breschi MC; Campa M; Batoni G; Brancatisano FL; Bianucci AM
Chem Biol Drug Des; 2011 Oct; 78(4):718-24. PubMed ID: 21756283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
